New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
18:58 EDTCLDX, SIMO, YUM, OGXI, HOLX, THO, IDIX, BIDUOn The Fly: After Hours Movers
UP AFTER PRELIMINARY EARNINGS: Thor Industries (THO), up 3.7% after preliminary Q2 revenue beats estimates... DOWN AFTER EARNINGS: Yum! Brands (YUM), down 5.4% after cutting its FY13 EPS view, reporting Q4 China SSS down 6%... Baidu (BIDU), down 5.2%... Hologic (HOLX), down 4.1%... Silicon Motion (SIMO), down 10.9% after reporting Q4 earnings and saying it sees Q1 revenue own 15%-25% sequentially... ALSO LOWER: Idenix (IDIX), down 5.9% after announcing it had discontinued clinical development for a hepatitis C treatment... OncoGenex (OGXI), down 3.3% after disclosing the resignation of its CFO... Celldex (CLDX), down 3.3% after filing to sell $75M in common stock.
News For THO;YUM;BIDU;HOLX;SIMO;IDIX;OGXI;CLDX From The Last 14 Days
Check below for free stories on THO;YUM;BIDU;HOLX;SIMO;IDIX;OGXI;CLDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 14, 2014
07:23 EDTYUMJapan sees first bird flu outbreak since 2011, Mainichi reports
Subscribe for More Information
April 11, 2014
12:44 EDTBIDUHedge funds initiating shorts on Priceline, Amazon, Twitter, CNBC says
Subscribe for More Information
April 9, 2014
08:33 EDTBIDU, BIDUBaidu revenue growth could beat expectations, says CLSA
Subscribe for More Information
08:31 EDTBIDU, BIDUSpeculation of Baidu interest in Ctrip.com logical, says CLSA
Subscribe for More Information
07:23 EDTIDIXEuropean Association for the Study of the Liver to hold annual meeting
Subscribe for More Information
April 8, 2014
11:47 EDTIDIXIdenix price target raised to $9 from $6 at Leerink
Leerink raised Idenix's price target to $9 from $6 citing positive IDX21437 data.
10:51 EDTBIDUCtrip, Qunar rise after Bloomberg says travel sites in deal talks
Subscribe for More Information
09:35 EDTBIDUActive equity options trading on open
Subscribe for More Information
09:09 EDTBIDUOn The Fly: Pre-market Movers
HIGHER: BioScrip (BIOS), up 6.7% after stock was named as a stock pick and a potential takeover target by Oscar Schafer while speaking on CNBC... Nokia (NOK), up 5% after deal to sell substantially all of its Devices & Services business to Microsoft (MSFT) receives regulatory approval in China... Ctrip.com (CTRP), up 4.6% after Bloomberg said, citing sources, that the company is in talks with Baidu-controlled (BIDU) Qunar (QUNR) about a partnership or a potential merger... Plug Power (PLUG), up 4.6% after CEO discusses plan to expand fuel cells to trucks in interview... FireEye (FEYE), up 2.5% following upgrade at Wedbush... Twitter (TWTR), up 2% following initiation of coverage with a Buy rating at at Janney Capital... Nike (NKE), up 1.75% after upgraded at Stifel. LOWER: Gigamon (GIMO), down 23% after lowering revenue outlook, shares downgraded at Pacific Crest... LivePerson (LPSN), down 3% after announcing resignation of EVP, Worldside Sales, shares downgraded at Benchmark... Cisco (CSCO), down 0.5% following downgrade to Hold from Buy at Wunderlich.
07:54 EDTYUMYum! Brands testing new Super Chix concept, AdAge reports
Yum Brands will start testing Super Chix, a new concept restaurant, AdAge reports. This week, Super Chix will launch in Arlington, Texas, with a limited menu including chicken sandwiches, chicken tenders, fries, salads and custards. A spokesperson for Yum says the concept "may in the future be considered for international purposes." Reference Link
07:22 EDTBIDUQunar, Ctrip.com in talks on potential merger, Bloomberg says
Chinese travel websites Qunar (QUNR) and Ctrip.com (CTRP) are in talks on a range of possibilities, from a partnership to a full merger, according to Bloomberg, citing two people with direct knowledge of the talks. Qunar, which went public last year in the U.S., is majority owned by Chinese search giant Baidu (BIDU), which recently had over 58% of voting power via its stake. Reference Link
April 7, 2014
16:28 EDTIDIXOn The Fly: Closing Wrap
Subscribe for More Information
16:02 EDTCLDXCelldex says CDX-014 to enter clinical development
Celldex Therapeutics reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Based on the results, CDX-014 will enter clinical development. CDX-014 is an antibody drug conjugate that targets the protein TIM-1. "The data presented today confirm that CDX-014 effectively targets the tumor marker TIM-1 in vitro and elicits significant anti-tumor activity in key models. We are currently completing manufacturing and IND-enabling studies and anticipate that CDX-014 will enter Phase 1 clinical studies in renal cell carcinoma and potentially other TIM-1 expressing tumors in 2015," said Tibor Keler, senior VP and Chief Scientific Officer of Celldex.
14:16 EDTBIDUBaidu volatility increases as shares pull back to six-month low
Subscribe for More Information
13:31 EDTIDIXIdenix risk/reward remains favorable, says UBS
UBS said Idenix's IDX21437 update this morning supports its favorable risk/reward thesis. Shares are Buy rated with an $11 price target.
07:15 EDTIDIXIdenix announces promising clinical data, continued progress in HCV programs
Idenix Pharmaceuticals announced continued progress of the Company's program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus, or HCV, infection. Idenix is reporting potent antiviral activity of mean maximum 4.2-4.3 log10 IU/mL reductions for patients infected with HCV genotype 1, 2 or 3 receiving 300 mg once daily of IDX21437 in the seven-day proof-of-concept portion of a phase I/II clinical trial. Based on this progress, the Company's goal is to initiate a combination clinical trial of IDX21437 and samatasvir, a pan-genotypic NS5A inhibitor, in mid-2014. In addition, Idenix has selected a follow-on uridine-based nucleotide prodrug, IDX21459, from its ongoing nucleotide discovery program and initiated enrollment for the healthy volunteer portion of a phase I clinical trial. In January, Idenix initiated the seven-day proof-of-concept portion of a phase I/II clinical trial for IDX21437. The trial completed enrollment of 44 treatment-nave, genotype, or GT, 1, 2 or 3 HCV-infected patients. Patients were randomized to receive once-daily doses of placebo, 50 mg, 150 mg, or 300 mg of IDX21437 for seven days. In April 2014, Idenix initiated enrollment for the healthy volunteer portion of a phase I clinical trial of IDX21459 in Europe. This portion of the study is expected to enroll approximately 50 healthy volunteers and will evaluate once-daily doses of IDX21459 ranging from 10 mg 300 mg. The proof-of-concept portion of the study is expected to enroll a total of 40 treatment-nave, genotype 1 HCV-infected patients who will receive once-daily doses of placebo, 50 - 300 mg of IDX21459 for seven days. IDX21459 has shown a favorable preclinical profile including potent, pan-genotypic activity and favorable safety with respect to cardiac, mitochondrial and genotoxicity assessments.
April 4, 2014
09:50 EDTCLDXCelldex management to meet with Guggenheim
Meetings to be held in New York on April 10-11 hosted by Guggenheim.
07:43 EDTBIDUBaidu market leading search share in China rose in March, Marbridge Daily says
Subscribe for More Information
April 3, 2014
08:27 EDTCLDXLeerink's biotech analyst holds a dinner meeting update
Biotech Analyst Liang holds an update from the AACR's Annual Meeting to discuss some of the presentations including PFE/AMGN's Palbociclib, PBYI/PFE's Neratinib, as well as other new agents for breast cancer from LLY, MDVN and CLDX, in San Diego on April 7 at 9 pm.
08:11 EDTCLDXCelldex to present CDX-014 preclinical proof of concept data at AACR
Celldex Therapeutics announced that data from preclinical studies evaluating the anti-tumor activity of the antibody-drug conjugate CDX-014 will be presented at the American Association of Cancer Research, or AACR, Annual Meeting 2014 in San Diego, California, April 5-9. CDX-014 targets the protein TIM-1, which is upregulated in several cancers, including renal and ovarian carcinomas.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use